Veronika Igl

Veronika Igl

Auto-generated profile, based on publicly available information

Veronika Igl

Institute of Clinical Pharmacology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAdrian Gottschlich
Adrian Gottschlich
MTMoritz Thomas
Moritz Thomas
RGRuth Grünmeier
Ruth Grünmeier
SLStefanie Lesch
Stefanie Lesch
LRLisa Rohrbacher
Lisa Rohrbacher
SKSebastian Kobold
Sebastian Kobold

3 April 2025 in Blood
Verified
Journal Article
Open access
AGAdrian Gottschlich
Adrian Gottschlich
RGRuth Grünmeier
Ruth Grünmeier
GHGordon Victor Hoffmann
Gordon Victor Hoffmann
SNSayantan Nandi
Sayantan Nandi
VKVladyslav Kavaka
Vladyslav Kavaka
SKSebastian Kobold
Sebastian Kobold
The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For young patients with classic Hodgkin lymphoma (cHL), immunotherapies provide the possibility to lessen long-term, treatment-related toxicities. However, suitable therapeutic targets are lacking. By integrating single-cell dissection of the tumor landscape and an in-depth, single-cell–based off-tumor antigen prediction, we identify CD86 as a promising therapeutic target in cHL. CD86 is highly expressed on Hodgkin and Reed-Sternberg cancer cells and cHL-specific tumor-associated macrophages. We reveal CD86–CTLA-4 as a key suppressive pathway in cHL, driving T-cell exhaustion. Cellular therapies targeting CD86 had extraordinary efficacy in vitro and in vivo and were safe in immunocompetent mouse models without compromising bacterial host defense in sepsis models. Our results prove the potential value of anti-CD86 immunotherapies for treating cHL.

18 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAdrian Gottschlich
Adrian Gottschlich
VKVladyslav Kavaka
Vladyslav Kavaka
TJThomas Alexander Janert
Thomas Alexander Janert
VIVeronika Igl
Veronika Igl
ECEmanuele Carlini
Emanuele Carlini
SKSebastian Kobold
Sebastian Kobold
Immunotherapy in acute myeloid leukemia (AML) is constrained by a hostile bone marrow niche. Here we identify atypical memory B cells (B atyp ) as a suppressive population within this microenvironment. Across single cell and flow cytometry cohorts, B atyp were expanded in AML, and their molecular and phenotypic profiles resembled those of atypical B cells associated with chronic inflammatory conditions. B atyp were polarized within the AML microenvironment, and this was amplified by CAR T cell–AML interactions. Mechanistically, polarization was dependent on Toll-like receptor, interferon and CD70–CD27 signaling. B atyp suppressed T cell and CAR T cell responses via PD-1-and TGF-β-R signaling, and were enriched in non-responding patients with AML and myeloma. CD180-directed CAR T cells, targeting an antigen shared by B atyp and AML blasts, resisted suppression in vitro and cleared disease in B cell–humanized xenografts while sparing hematopoietic stem cells, with B cell engagement further enhancing their expansion. CAR T cells thus reinforce their own suppressive niche through B atyp polarization, a constraint that can be relieved by dual blast- and B cell-targeting strategies.